JP2016104045A5 - - Google Patents

Download PDF

Info

Publication number
JP2016104045A5
JP2016104045A5 JP2016043151A JP2016043151A JP2016104045A5 JP 2016104045 A5 JP2016104045 A5 JP 2016104045A5 JP 2016043151 A JP2016043151 A JP 2016043151A JP 2016043151 A JP2016043151 A JP 2016043151A JP 2016104045 A5 JP2016104045 A5 JP 2016104045A5
Authority
JP
Japan
Prior art keywords
cell
glycoprotein
seq
protein comprises
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016043151A
Other languages
English (en)
Japanese (ja)
Other versions
JP6211642B2 (ja
JP2016104045A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016104045A publication Critical patent/JP2016104045A/ja
Publication of JP2016104045A5 publication Critical patent/JP2016104045A5/ja
Application granted granted Critical
Publication of JP6211642B2 publication Critical patent/JP6211642B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016043151A 2009-06-02 2016-03-07 フコシル化欠損細胞 Expired - Fee Related JP6211642B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18340009P 2009-06-02 2009-06-02
US61/183,400 2009-06-02
US34885810P 2010-05-27 2010-05-27
US61/348,858 2010-05-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014251541A Division JP2015051021A (ja) 2009-06-02 2014-12-12 フコシル化欠損細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016202634A Division JP2017006147A (ja) 2009-06-02 2016-10-14 フコシル化欠損細胞

Publications (3)

Publication Number Publication Date
JP2016104045A JP2016104045A (ja) 2016-06-09
JP2016104045A5 true JP2016104045A5 (2) 2016-12-01
JP6211642B2 JP6211642B2 (ja) 2017-10-11

Family

ID=42338231

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012514045A Expired - Fee Related JP5744856B2 (ja) 2009-06-02 2010-06-01 フコシル化欠損細胞
JP2014251541A Withdrawn JP2015051021A (ja) 2009-06-02 2014-12-12 フコシル化欠損細胞
JP2016043151A Expired - Fee Related JP6211642B2 (ja) 2009-06-02 2016-03-07 フコシル化欠損細胞
JP2016202634A Pending JP2017006147A (ja) 2009-06-02 2016-10-14 フコシル化欠損細胞

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012514045A Expired - Fee Related JP5744856B2 (ja) 2009-06-02 2010-06-01 フコシル化欠損細胞
JP2014251541A Withdrawn JP2015051021A (ja) 2009-06-02 2014-12-12 フコシル化欠損細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016202634A Pending JP2017006147A (ja) 2009-06-02 2016-10-14 フコシル化欠損細胞

Country Status (16)

Country Link
US (8) US8409838B2 (2)
EP (3) EP2808393B1 (2)
JP (4) JP5744856B2 (2)
KR (2) KR101441437B1 (2)
CN (1) CN102459603B (2)
AU (1) AU2010256753B2 (2)
BR (1) BRPI1010035A2 (2)
CA (1) CA2764370C (2)
DK (3) DK2438171T3 (2)
ES (2) ES2661074T3 (2)
HU (1) HUE038596T2 (2)
IL (1) IL216624A (2)
PL (3) PL2808393T3 (2)
SG (1) SG176251A1 (2)
TW (1) TWI513818B (2)
WO (1) WO2010141478A1 (2)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
DK2438171T3 (en) 2009-06-02 2015-01-26 Regeneron Pharma Fucosylerings-deficient cells
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
WO2015057393A1 (en) * 2013-10-01 2015-04-23 University Of Wyoming Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production recombinant glycoproteins
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
EP3149034B1 (en) * 2014-05-30 2022-07-13 New England Biolabs, Inc. Deglycosylation reagents and methods
WO2016007506A1 (en) * 2014-07-07 2016-01-14 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use
CN105671109B (zh) * 2014-11-20 2019-08-23 中国人民解放军军事医学科学院生物工程研究所 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法(二)
WO2017079165A1 (en) * 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
US20190161543A1 (en) * 2016-01-06 2019-05-30 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
US11512144B2 (en) * 2016-04-20 2022-11-29 Regeneran Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing loci
EA201892137A1 (ru) 2016-04-20 2019-03-29 Регенерон Фармасьютикалз, Инк. Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EP3339444A1 (en) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
BR112020019559A2 (pt) 2018-03-26 2021-01-12 Amgen Inc. Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
EP3818149A4 (en) * 2018-08-29 2022-03-23 United Biopharma Inc Afucosylated antibodies and manufacture thereof
WO2020090747A1 (ja) 2018-10-29 2020-05-07 株式会社免疫生物研究所 抗hiv抗体及びその製造方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
JP2023527352A (ja) 2020-05-26 2023-06-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗sars-cov-2-スパイク糖タンパク質抗体及び抗原結合断片
CA3181026A1 (en) 2020-06-03 2021-12-09 Samit GANGULY Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
CN112843234B (zh) * 2021-01-20 2022-09-06 四川大学华西第二医院 一种调控生物机体内gdp-甘露糖的浓度的装置
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
EP4359440A1 (en) 2021-06-22 2024-05-01 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof
IL310012A (en) 2021-07-14 2024-03-01 Regeneron Pharma Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
WO2023167847A2 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Bioreactor for antibody production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006070A (en) 1909-05-11 1911-10-17 George Walter Durbrow Method of and means for extracting micro-organisms and solids from water.
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP2001145488A (ja) 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のgdp−4−ケト−6−デオキシ−d−マンノース−3,5−エピメラーゼ−4−レダクターゼ遺伝子
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
ES2639222T5 (es) * 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020150968A1 (en) 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
WO2002057423A2 (en) 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
KR100585140B1 (ko) 2004-04-26 2006-05-30 삼성전자주식회사 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
US20090208500A1 (en) 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
AU2008227024A1 (en) 2007-03-07 2008-09-18 Glycofi, Inc. Production of glycoproteins with modified fucosylation
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP5662149B2 (ja) 2008-08-13 2015-01-28 協和発酵キリン株式会社 遺伝子組換えプロテインs組成物
DK2438171T3 (en) 2009-06-02 2015-01-26 Regeneron Pharma Fucosylerings-deficient cells
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof

Similar Documents

Publication Publication Date Title
JP2016104045A5 (2)
AR132934A2 (es) Medio de cultivo celular suplementado con taurina y métodos de utilización
AR120511A2 (es) Producción de proteínas heteromultiméricas
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
MY189819A (en) Genetically modified cells and uses thereof
EP3597664A3 (en) Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
IL310186B1 (en) Plasma kallikrein binding proteins
HK1218297A1 (zh) 用於生产单克隆抗体的改进方法
JP2017505620A5 (2)
MX2022007840A (es) Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla4) y uso del mismo.
MX2019010575A (es) Metodo para producir anticuerpos multiespecificos.
JP2015532096A5 (2)
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał
MX381844B (es) Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos
EP4374913A3 (en) Novel human serum albumin mutant
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
PL439807A1 (pl) Sposoby oczyszczania przeciwciał i ich kompozycje
EA202091349A1 (ru) Способы культивирования клеток
BR112016028538A2 (pt) processo de produção de proteína glicosilada, processos de produção de proteína de fusão e anticorpo monoclonal e fragmento do mesmo, processo de produção de proteína de fusão tnfr-fc, proteína de fusão ou anticorpo monoclonal e fragmento do mesmo
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
PH12020552252A1 (en) Influenza virus hemagglutinin mutants
AR097805A1 (es) Células de cambio de temperatura para la expresión de alto rendimiento de polipéptidos en levadura y otros transformados
JP2016512251A5 (2)
JP2015536347A5 (2)
MX2020002283A (es) Vacuna recombinante contra la enteropatia proliferativa en animales.